Jill Fairless

Dr. Jill Fairless

University of Florida, Gainesville, Florida, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 January 2022 in The American Journal on Addictions
Verified
Journal Article
Open access
PDF file
Lisa MerloLisa Merlo
Lisa Merlo
MCMichael D. Campbell
Michael D. Campbell
CSCorinne Shea
Corinne Shea
WWWilliam White
William White
GSGregory E. Skipper
Gregory E. Skipper
RDRobert L. DuPont
Robert L. DuPont
Background and Objectives: Physician health programs (PHPs) have demonstrated efficacy, but their mechanism of influence is unclear. This study sought to identify essential components of PHP care management for substance use disorder (SUD), and to assess whether positive outcomes are sustained over time.Methods: Physicians with DSM‐IV diagnoses of Substance Dependence and/or Substance Abuse who had successfully completed a PHP monitoring agreement at least 5 years before the study (N = 343) were identified as eligible. Of the 143 (42%) that could be reached by phone, 93% (n = 133; 86% male) completed the anonymous online survey.Results: Virtually all PHP program components were rated as being at least “somewhat helpful” in promoting recovery, with the plurality of respondents rating almost all components as “extremely helpful.” The top‐rated components were: signing a PHP monitoring agreement, participation in the PHP, formal SUD treatment, and attending 12‐step meetings, with each receiving a mean rating of at least 6.2 out of 7. Notably, 88% of respondents endorsed continued participation in 12‐step fellowships. Despite the significant financial burden of PHP participation, 85% of respondents reported they believed the total financial cost of PHP participation was “money well spent.”Discussion and Conclusions: Components of PHP monitoring were viewed as acceptable and helpful to physicians who completed the program, and outcomes were generally sustained over 5 years. More studies are needed to confirm these preliminary findings.Scientific Significance: This study documents the perceived cost‐benefit of participation in a PHP among a small sample of program completers.

17 August 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Shu HuangShu Huang
Shu Huang
MLMotomori O. Lewis
Motomori O. Lewis
YBYuhua Bao
Yuhua Bao
PAPrakash Adekkanattu
Prakash Adekkanattu
LALauren E. Adkins
Lauren E. Adkins
WCWei Hsuan Lo Ciganic
Wei Hsuan Lo Ciganic
Suicide is a leading cause of death in the US. Patients with pain conditions have higher suicidal risks. In a systematic review searching observational studies from multiple sources (e.g., MEDLINE) from 1 January 2000–12 September 2020, we evaluated existing suicide prediction models’ (SPMs) performance and identified risk factors and their derived data sources among patients with pain conditions. The suicide-related outcomes included suicidal ideation, suicide attempts, suicide deaths, and suicide behaviors. Among the 87 studies included (with 8 SPM studies), 107 suicide risk factors (grouped into 27 categories) were identified. The most frequently occurring risk factor category was depression and their severity (33%). Approximately 20% of the risk factor categories would require identification from data sources beyond structured data (e.g., clinical notes). For 8 SPM studies (only 2 performing validation), the reported prediction metrics/performance varied: C-statistics (n = 3 studies) ranged 0.67–0.84, overall accuracy(n = 5): 0.78–0.96, sensitivity(n = 2): 0.65–0.91, and positive predictive values(n = 3): 0.01–0.43. Using the modified Quality in Prognosis Studies tool to assess the risk of biases, four SPM studies had moderate-to-high risk of biases. This systematic review identified a comprehensive list of risk factors that may improve predicting suicidal risks for patients with pain conditions. Future studies need to examine reasons for performance variations and SPM’s clinical utility.

1 January 2026 in Depression and Anxiety
Verified
Journal Article
Open access
PDF file
Shu HuangShu Huang
Shu Huang
AGAmie J. Goodin
Amie J. Goodin
JFJill Fairless
Jill Fairless
JGJingchuan Guo
Jingchuan Guo
Jiang BianJiang Bian
Jiang Bian
TJTianze Jiao
Tianze Jiao
Background: The cooccurrence of posttraumatic stress disorder (PTSD) and opioid use heightens suicide risk. We aimed to develop and validate a machine learning‐based suicide prediction model (SPM) to identify PTSD patients prescribed opioids who are at risk of suicide within 6‐month prediction intervals. Methods: Using 2016–21 OneFlorida+ data, we compared the predictive performance of multiple models, including least absolute shrinkage and selection operator (LASSO) regression, gradient boosting machines (GBMs), random forest (RF), and deep neural networks (DNNs). The best‐performing SPM was selected to predict 6‐month suicide risks among adult PTSD patients who received opioids. The index date was the first day when both an opioid prescription and a PTSD diagnosis occurred within 180 days. We divided the 2016–18 cohort into training and internal validation datasets (2:1 ratio), applying machine learning models to the training dataset to predict suicide‐related outcomes. We evaluated model prediction performance using various metrics on internal (2016–18) and external (2019–21) validation cohorts. Results: Among 5578 patients (age = 38.1 ± 11.1, female = 83.2%) in the 2016–18 cohort, 709 (12.7%) patients had at least one suicide‐related outcome during follow‐up. The final RF model selected 271/299 covariates, with C‐statistics, accuracy, sensitivity, specificity, and precision being 83.6% (81.7%−85.9%), 86.2% (85.2%−87.1%), 65.0% (59.8%−70.1%), 87.6% (86.7%−88.5%), and 26.6% (24.6%−28.8%), respectively. We classified intervals into 10 suicide‐risk subgroups based on the predicted probabilities, with 79.2% of suicide intervals captured in the top 3 decile subgroups. We observed similar findings in the 2019–21 cohort ( n = 4849), with C‐statistics, accuracy, sensitivity, specificity, and precision being 83.6% (82.2%−84.9%), 87.0% (86.5%−87.6%), 65.3% (61.7%−68.7%), 88.2% (87.6%−88.7%), and 22.3% (21.1%−23.5%), respectively. Conclusions: Our SPM performed well in internal and external validations. It may serve as a feasible tool to identify patients at risk of suicide, helping prioritize preventive interventions, and enabling providers to allocate time and resources more efficiently to patients who may benefit from closer follow‐up.

1 December 2022
Verified
Book Chapter
Closed access
PDF file
Lisa MerloLisa Merlo
Lisa Merlo
APAlexis Polles
Alexis Polles
JFJill Fairless
Jill Fairless
WGWilliam M. Greene
William M. Greene
KTKathryn M. Thompson
Kathryn M. Thompson

6 May 2025 in JMIR Preprints
Verified
Preprint
Open access
Shu HuangShu Huang
Shu Huang
TJTianze Jiao
Tianze Jiao
JGJingchuan Guo
Jingchuan Guo
JFJill Fairless
Jill Fairless
Jie XuJie Xu
Jie Xu
AGAmie J. Goodin
Amie J. Goodin
BACKGROUND Health care providers must carefully monitor patients receiving long-term opioid therapy (LTOT) to minimize risks and maximize benefits. Yet, algorithms to support intervention during patient encounters are lacking, with accurate LTOT identification in routine care being the essential first step. OBJECTIVE This study aims to develop and validate an LTOT identification algorithm using electronic health record (EHR) data. METHODS In this cross-sectional study, we used 2016-2021 OneFlorida+ EHR data linked with Florida Medicaid claims to identify patients aged ≥18 years who received opioid prescriptions. The main outcome was the first LTOT episode in the algorithm development (2016-2018) and validation (2019-2021) periods. A Medicaid claims-based LTOT algorithm served as the reference standard, defined as ≥90 days of continuous opioid use with ≤15-day gaps. Given strong correlations among covariates, an elastic net regression model was applied to identify LTOT episodes in EHR data using patient characteristics, clinically relevant features, and medication use, and to evaluate the model’s classification performance. We randomly split the 2016-2018 cohort into development and internal validation datasets (2:1 ratio), stratified by LTOT incidence. External validation was performed using 2019-2021 data. RESULTS Among 64,206 eligible patients identified in 2016-2018 (mean age 35.7, SD 12.3 years; 51,421/64,206, 80.1% female), a total of 8899 (13.9%) had LTOT. Among 50,009 eligible patients identified in 2019-2021 (mean age 37.3, SD 12.5 years; 39,866/50,009, 79.7% female), a total of 6000 (12%) had LTOT. The model selected 29 out of 131 candidate features. Among 2967 individuals with LTOT in the 2016-2018 OneFlorida+ internal validation dataset, a total of 2176 (73.3%) individuals were identified in the top 3 deciles of risk scores. The model achieved a C-statistic of 0.83 (95% CI 0.82-0.84), with 73.4% (95% CI 71.8%-75%) sensitivity, 76.8% (95% CI 76.2%-77.4%) specificity, 33.8% (95% CI 33.1%-34.6%) precision, 76.3% (95% CI 75.8%-76.9%) accuracy, and an F1-score of 0.46. In the 2019-2021 OneFlorida+ external validation dataset, a total of 75.5% (4527/6000) individuals were correctly captured in the top 3 risk subgroups. The model achieved a C-statistic of 0.83 (95% CI 0.83-0.84), with 78.8% (95% CI 77.8%-79.9%) sensitivity, 73.3% (95% CI 72.9%-73.7%) specificity, 28.7% (95% CI 28.3%-29.1%) precision, 73.9% (73.6%-74.3%) accuracy, and an F1-score of 0.42. CONCLUSIONS The EHR-based LTOT algorithm showed comparable accuracy to the claims-based reference and may support risk stratification and inform decision-making during clinical encounters.

10 December 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
Shu HuangShu Huang
Shu Huang
TJTianze Jiao
Tianze Jiao
JGJingchuan Guo
Jingchuan Guo
JFJill Fairless
Jill Fairless
Jie XuJie Xu
Jie Xu
AGAmie J. Goodin
Amie J. Goodin
Background: Health care providers must carefully monitor patients receiving long-term opioid therapy (LTOT) to minimize risks and maximize benefits. Yet, algorithms to support intervention during patient encounters are lacking, with accurate LTOT identification in routine care being the essential first step. Objective: This study aims to develop and validate an LTOT identification algorithm using electronic health record (EHR) data. Methods: In this cross-sectional study, we used 2016-2021 OneFlorida+ EHR data linked with Florida Medicaid claims to identify patients aged ≥18 years who received opioid prescriptions. The main outcome was the first LTOT episode in the algorithm development (2016-2018) and validation (2019-2021) periods. A Medicaid claims-based LTOT algorithm served as the reference standard, defined as ≥90 days of continuous opioid use with ≤15-day gaps. Given strong correlations among covariates, an elastic net regression model was applied to identify LTOT episodes in EHR data using patient characteristics, clinically relevant features, and medication use, and to evaluate the model’s classification performance. We randomly split the 2016-2018 cohort into development and internal validation datasets (2:1 ratio), stratified by LTOT incidence. External validation was performed using 2019-2021 data. Results: Among 64,206 eligible patients identified in 2016-2018 (mean age 35.7, SD 12.3 years; 51,421/64,206, 80.1% female), a total of 8899 (13.9%) had LTOT. Among 50,009 eligible patients identified in 2019-2021 (mean age 37.3, SD 12.5 years; 39,866/50,009, 79.7% female), a total of 6000 (12%) had LTOT. The model selected 29 out of 131 candidate features. Among 2967 individuals with LTOT in the 2016-2018 OneFlorida+ internal validation dataset, a total of 2176 (73.3%) individuals were identified in the top 3 deciles of risk scores. The model achieved a C-statistic of 0.83 (95% CI 0.82-0.84), with 73.4% (95% CI 71.8%-75%) sensitivity, 76.8% (95% CI 76.2%-77.4%) specificity, 33.8% (95% CI 33.1%-34.6%) precision, 76.3% (95% CI 75.8%-76.9%) accuracy, and an F1-score of 0.46. In the 2019-2021 OneFlorida+ external validation dataset, a total of 75.5% (4527/6000) individuals were correctly captured in the top 3 risk subgroups. The model achieved a C-statistic of 0.83 (95% CI 0.83-0.84), with 78.8% (95% CI 77.8%-79.9%) sensitivity, 73.3% (95% CI 72.9%-73.7%) specificity, 28.7% (95% CI 28.3%-29.1%) precision, 73.9% (73.6%-74.3%) accuracy, and an F1-score of 0.42. Conclusions: The EHR-based LTOT algorithm showed comparable accuracy to the claims-based reference and may support risk stratification and inform decision-making during clinical encounters.